Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD | |
Domchek, Susan M.; Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Armstrong, Anne; Conte, Pierfranco | |
刊名 | CANCER RESEARCH
![]() |
2018 | |
卷号 | 78期号:4 |
ISSN号 | 0008-5472 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3535667 |
专题 | 吉林大学白求恩第一医院 |
推荐引用方式 GB/T 7714 | Domchek, Susan M.,Robson, Mark,Im, Seock-Ah,et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD[J]. CANCER RESEARCH,2018,78(4). |
APA | Domchek, Susan M..,Robson, Mark.,Im, Seock-Ah.,Senkus, Elzbieta.,Xu, Binghe.,...&Tung, Nadine.(2018).Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.CANCER RESEARCH,78(4). |
MLA | Domchek, Susan M.,et al."Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD".CANCER RESEARCH 78.4(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论